CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 287 enrolled
Drug / intervention
doxorubicin hydrochloride +11 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00302003
NCT00302003Phase 3Completed
CompareCT.gov

A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease

Children's Oncology Group·interventional·Posted Mar 13, 2006·Updated Mar 30, 2021

In Brief

A Phase 3 clinical trial evaluating radiation therapy, doxorubicin hydrochloride, and 10 other interventions for Childhood Favorable Prognosis Hodgkin Lymphoma and 5 related conditions. Completed, enrolled 287 participants across 1 site.

Detailed Summary

This phase III trial is studying how well combination chemotherapy works when given before radiation therapy and/or additional chemotherapy in treating young patients with newly diagnosed Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving more than one drug (combination chemotherapy) and giving them together with radiation therapy may kill more cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChildhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2006
Enrollment StartFeb 1, 2006
Primary CompletionMar 1, 2012
Study CompletionJun 30, 2019
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 20.3 years ago

Interventions

radiation therapyradiation

Undergo radiation therapy

doxorubicin hydrochloridedrug

Given IV

vincristine sulfatedrug

Given IV

prednisonedrug

Given orally

cyclophosphamidedrug

Given IV

ifosfamidedrug

Given IV

vinorelbine tartratedrug

Given IV

dexamethasonedrug

Given IV

etoposide phosphatedrug

Given IV

cisplatindrug

Given IV

cytarabinedrug

Given IV

filgrastimbiological

Given IV or subcutaneously